NasdaqGS:INCYBiotechs
Incyte (INCY) Is Up 6.2% After Positive 54-Week HS and IO Combo Data - What's Changed
In late March 2026, Incyte reported 54-week Phase 3 STOP-HS data showing durable efficacy and a consistent safety profile for its oral JAK1 inhibitor povorcitinib in adults with moderate to severe hidradenitis suppurativa.
Separately, Adagene recently announced a clinical collaboration under which Incyte will run a Phase 1 trial combining its TGFßR2 × PD-1 bispecific antibody INCA33890 with Adagene’s muzastotug in hard-to-treat microsatellite stable colorectal cancer, underscoring Incyte’s...